Nanjing University of Chinese Medicine (NJUCM)   中文版   |   Home   |  Contact Us  
     
 
 
  • Focus01
  • Focus02
  • Focus03
  • Focus04
  • Focus05
 
NJUCM
News
Events
Focus
 
 
Prof. Qin Shukui Publishing Article on Tumor Immunotherapies in Science Supplement
 
On February 2, 2018, the world’s leading academic journal Science produced a latest supplement titled Precision medicine and cancer immunology in China, which was written by ten plus Chinese leading experts such academicians Wang Hongyang and Yu Jinmin. The supplement gave a detailed description of the status quo of precision medicine and the past, present and future of tumor immunotherapies in China. Prof. Qin Shukui, faculty of Bayi Hospital affiliated to NJUCM published a paper titled Current status of immunotherapy in advanced HCC in the Science supplement.

Prof. Qin Shukui’s paper dealt with the current situation of immunotherapies to liver cancer. His paper indicated that hepatocellular carcinoma (HCC), is one of the most common cancers worldwide, with especially high prevalence in China and a growing incidence. As one of the leading causes of cancer-related deaths, HCC was responsible for an estimated 746,000 deaths worldwide in 2012. China alone accounted for more than 50% of both new HCC cases and HCC-related deaths globally. Due to difficulties in early diagnosis, most HCC cases are locally advanced or show distant metastases at the time of diagnosis. These patients generally have a poor prognosis, with median survival of 6 to 20 months, and a five-year survival rate of less than 16%. In recent years, Tumor immunotherapies, especially immune checkpoint inhibitors have demonstrated preliminary but promising clinical activity in patients with HCC, and several large randomized phase 3 clinical trials of these treatments are currently underway. Despite the limited progress and challenges in the development of HCC treatment in the past decades, there is hope on the horizon. With the joint efforts of all parts, more safe and effective treatments for HCC patients will be developed in the future.
NJUCM was the only correspondent institution to Prof. Qin Shukui’s article, the link of which is as following,

http://www.sciencemag.org/sites/default/files/GiantCRO_supplement.pdf





  Updated:2018-2-6    
ADD:138 Xianlin Rd,Nanjing 210023,P.R.C Tel:(+86)25-85811079 Fax:(+86)25-85811078
All Rights Reserved © Nanjing University of Chinese Medicine